We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AI Software Needs a ‘Distinct’ Regulatory Review Process, Researchers Say
AI Software Needs a ‘Distinct’ Regulatory Review Process, Researchers Say
To help prevent the approval of AI medical devices that “mirror or exacerbate” existing health disparities, the FDA should develop a “distinct regulatory process” for artificial intelligence (AI)-driven software as a medical device (SaMD), say several academic researchers.